Geneva, Geneva, Switzerland
Seasoned professional with 20+ years experience in pharmaceutical companies, which twelve years in major Top 10, Chris has acquired Global experience at the headquarter of US company for more than 5 years leading a strategic role as Head of Global Pricing & Market Access for a portfolio composed by marketed brands and new products in oncology, a universally acknowledged critical sector for the future growth of pharmaceutical companies. In this role, Chris gained worldwide access and reimbursement for Alimta in 2nd and 1st line non-squamous NSCLC, as well as for switch and continuation maintenance therapy in non-squamous NSCLC, while maximizing the revenue with Gemzar facing a patent loss. Preparing for the future, he integrated the ImClone business and developed the strategy to launch Necitumumab in squamous NSCLC and Ramucirumab in mGC, mHCC, mCRC and 2nd line NSCLC. In his previous roles, Chris scope of responsibility did include the management of Corporate Affairs, Regulatory Affairs, Quality Assurance, Medical Affairs, Legal Affairs, Public Relations, Crisis Management while building close-knit relationship with government bodies and trade associations to achieve and maintain optimal market access for patients. Chris leadership skills include the management of small to mid-sized teams and the development of broad and complex network across functions and geographies, with the ability to speak 4 languages and easily evolve in multi cultural environment.
Operation of pharmacy business, including acquisition and sale Purchase, sale, import, export, manufacture of products and articles in the pharmaceutical business Participate in industrial and commercial companies to provide technical and administrative services
Provide Global & Local pricing & market access capabilities and expertise to Biotech and Pharma companies. Bridge the relationship gap between Pharma companies and Key Stakeholders providing a premium and trusted partnership to validate or test proof Global & Local pricing and market access strategies during early phases, before launch and along the life cycle management. Provide Quality support and expertise to local Pharma companies to successfully pass ISOPTh audit and acquire Swiss MAH autorisation with SwissMedic in order to market their products.
Coordinate all Pricing & Market Access activities in EU and Canada for new products pipeline (multiple sclerosis, soft tissue sarcoma, merkel cell carcinoma, pancreatic cancer, lung cancer).
EM Br log 1
Develop Pricing & Market Access strategy for oncology brands of one of the Top 10 Pharmaceutical Company with direct reporting line to VP Global Brands Oncology and VP International Market Oncology. Manage a team of 5 high skilled managers in charge of existing and new products to implement directly pricing and market access strategy in major markets (US, JP, Canada, Australia, EU M5) and collaborate with regional market access leaders for emerging markets (China, Turkey, Brazil, Korea, Taiwan) Decide on price strategies that maximize access and reimbursement and profitability. Decide on global goal, objectives, strategies and tactics related to market access, defining metrics to measure success, developing and providing coaching on negotiation strategies. Maintain expert knowledge on pricing reimbursement and access processes in major markets and how to apply this knowledge to enhance success in international markets.
Board member with signing authority reporting to the Managing Director and leading a team of 8 collaborators with an operating budget of CHF 1 million. Management of pricing & market access strategy, legal affairs, regulatory and safety affairs, quality processes, crisis management as well as building a close-knit relationship with government bodies and media as spokesman in charge of the company’s public relations. Key success stories: outstanding price protection during 4 years of our major brand Zyprexa, following a mandatory price drop and saving around CHF 3 millions, negative article on Prozac in “Le Matin” turned to positive impact, 3 legal cases regarding unfair competition successfully won, reimbursement of Forsteo with a selling cap model and of Cymbalta, Alimta and Byetta in a record timeframe, building of the whole compliance process of the Swiss affiliate from scratch and initiating affiliate public relation activities with Cialis patient events and Byetta press conferences.